Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ginkgo Bioworks Inc.

    NYSE: DNA · Real-Time Price · USD
    9.14
    0.20 (2.24%)
    At close: Jun 16, 2025, 3:59 PM
    9.14
    0.00%
    Pre-market: Jun 17, 2025, 05:57 AM EDT
    2.24%
    Bid 9.1
    Market Cap 534.98M
    Revenue (ttm) 237.42M
    Net Income (ttm) -472.07M
    EPS (ttm) -8.91
    PE Ratio (ttm) -1.03
    Forward PE -2.2
    Analyst Sell
    Ask 9.15
    Volume 781,274
    Avg. Volume (20D) 1,234,857
    Open 8.79
    Previous Close 8.94
    Day's Range 8.63 - 9.34
    52-Week Range 5.00 - 18.56
    Beta 1.26

    About DNA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DNA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for DNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +14.73%
    Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription
    2 months ago
    +11.23%
    Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
    news image

    1 day ago · accessnewswire.com

    Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

    STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resu...

    news image

    4 days ago · nypost.com

    23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm

    23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of milli...

    news image

    4 days ago · reuters.com

    23andMe's founder Anne Wojcicki wins bid for DNA testing firm

    Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.

    news image

    1 week ago · accessnewswire.com

    Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

    Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's pot...

    news image

    2 weeks ago · accessnewswire.com

    Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

    STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...

    news image

    2 weeks ago · businesswire.com

    Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

    SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundr...

    news image

    4 weeks ago · businessinsider.com

    23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

    Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.

    news image

    4 weeks ago · marketwatch.com

    23andMe sells its most valuable asset. Regeneron promises keep your DNA private.

    Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the th...

    news image

    1 month ago · accessnewswire.com

    Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

    - Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for  June ...

    news image

    1 month ago · accessnewswire.com

    Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

    STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will relea...

    Add to Watchlist